Urology Medical Lasers Global Market Report 2023 – By Laser Type (Holmium Laser System, Diode Laser System, Thulium Laser System, Other Laser Types), By Application (Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC), Other Applications), By End User (Hospital, Clinic, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Medical lasers are devices that treat or remove tissues using precisely focused light sources. The main types of medical lasers are solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. A solid-state laser system is a laser system that uses a gain medium as a solid instead of liquid, as in dye lasers and gas as in gas lasers. The applications involved are surgical, cosmetic, and dental. The end-users involved are ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular, and others. The global medical lasers market is segmented - 1) By Product Type: Solid State Laser Systems, Gas Laser Systems, Dye Laser Systems, Diode Laser Systems 2) By Application: Surgical, Cosmetic, Dental 3) By End Use: Ophthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular, Other End Users The global medical lasers market size grew from $5.56 billion in 2022 to $6.33 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical lasers market is expected to grow from $10.45 billion in 2027 at a CAGR of 13.3%. The increased demand for minimally invasive procedures contributed to the medical lasers market’s growth during the period. The surge in aesthetic and cosmetic procedures propelled the demand for minimally invasive surgeries worldwide. According to the article published by Beautynews in April 2021, the number of facial plastic surgery procedures in the USA in 2020 is approximately 56,084, and the one was the brow lift procedure is nearly 31,404. Thus, the high usage of medical lasers to perform minimally invasive aesthetic and cosmetic surgeries increases the demand for medical lasers market. Major players in the medical lasers market are El.En. S.p.A, Ellex Medical Lasers Ltd., Lumenis, Alcon Laboratories Inc., AngioDynamics Corp., American Medical Systems Inc., Biolase Inc., Bausch & Lomb Holdings, Cardiogenesis Corporation Inc., and Boston Scientific. The high cost of surgeries limits the growth of the medical laser market. The high cost of treatments involving medical lasers limited the adoption and demand for lasers used to perform minimally invasive surgeries. For instance, the average cost of LASIK surgery performed in the USA was $1,500 per eye in 2021. Therefore, the high and increasing cost of surgeries is likely to act as a restraint to the growth of the medical lasers market. Major players operating in the market are focusing on developing new innovative products with advanced techniques to serve healthcare professionals and their patients better. For instance, in March 2021, Solta Medical, a division of Bausch Health, launched Clear + Brilliant Touch Laser. The new laser a more comprehensive treatment protocol by providing the benefits of two wavelengths and easing the treatment process. In October 2021, Laser MD Medspa, a US-based medical spa services company, acquired Young Medical Spa for an undisclosed amount. The acquisition would expand the company’s footprint in the state of Pennsylvania by adding four locations. Young Medical is a US-based provider of a full suite of cosmetic and aesthetic treatments, including laser hair removal, botox treatment, and others. North America was the largest region in the medical lasers market in 2022. Asia-Pacific was the second largest region in the global medical lasers market share. The regions covered in the global medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The medical lasers market consists of sales of solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical lasers market research report is one of a series of new reports from The Business Research Company that provides medical lasers market statistics, including medical lasers industry global market size, regional shares, competitors with a medical lasers market share, detailed medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the medical lasers industry. This medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary incontinence & pelvic organ prolapse devices and equipment are used in the treatment of pelvic organ prolapse and urinary incontinence. Urinary incontinence (UI), also known as involuntary urination, is defined as uncontrolled leakage of urine caused by an overactive bladder. Pelvic organ prolapse (POP) is caused by defects in the supporting structures of the vagina. The main types in urinary incontinence & pelvic organ prolapse devices and equipment market are urinary incontinence devices and pelvic organ prolapse devices. The devices used to treat urinary incontinence are known as urinary incontinence devices. Artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters are examples of urinary incontinence devices. Vaginal mesh and vaginal pessaries are pelvic organ prolapse devices. The incontinence types are stress incontinence, urge incontinence, overflow incontinence, and functional incontinence. The various end-user involved are hospitals, clinics, ambulatory surgical centres, and home use. The global urinary incontinence & pelvic organ prolapse devices and equipment market is segmented - 1) By Type: Urinary Incontinence Devices, Pelvic Organ Prolapse Devices 2) By Urinary Incontinence Devices: Artificial Urinary Sphincters, Electrical Stimulation Devices, Urethral Slings, Catheters 3) By Pelvic Organ Prolapse Devices: Vaginal Mesh, Vaginal Pessary 4) By Incontinence Type: Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence 5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Use The global urinary incontinence & pelvic organ prolapse devices and equipment market size will grow from $0.43 billion in 2022 to $0.46 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global urinary incontinence & pelvic organ prolapse devices and equipment is expected to grow to $0.59 billion in 2027 at a CAGR of 6.3%. The increased prevalence rate for Pelvic organ prolapse (POP) as well as for urinary incontinence (UI) disorders has been driving the growth of urinary incontinence and pelvic organ prolapse (POP) devices and equipment market. The increasing prevalence rate has led manufacturers towards developing more accurate and efficient devices for the treatment of these disorders. The POP affects women of all ages, however, old age women are more prone to POP disorders. According to US FDA reports, the number of women who have POP is expected to increase by 46%, to 4.9 million, by 2050. According to a report published by the American Urological Association (AUA/SUFU), the prevalence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The prevalence rate of stress urinary incontinence is high in the poor nutritional status group, as it results in weakness of pelvic supports. This high prevalence rate is driving the demand for medical equipment for urinary incontinence & pelvic organ prolapse devices and equipment market. The urinary incontinence & pelvic organ prolapse devices and equipment market are being restrained by rising health issues due to the use of vaginal mesh for the treatment of UI and POP. Regulatory agencies such as FDA and NICE have devised new guidelines for the manufacturers to address these concerns. The vaginal mesh implants generally use a Polypropylene layer over the implants. Such vaginal mesh implants containing Polypropylene have caused severe medical complications in millions of women across the world. Therefore, manufacturers are now forced to develop an alternative material, such as polyurethane, which is better suited to be used by women without any health complications for treatment of pelvic organ prolapse and urine incontinence. For instance, on October 2022, after a 36 month study on transvaginal mesh for pelvic organ prolapsed, the food and drug administration, a US-based regulator of drugs and medical devices, decided to continue its ban on transvaginal mesh due to its low risk to benefit ratio. These concerns about the safety of vaginal mesh are resulting in stringent manufacturing regulations and affecting sales, thus restraining the UI and POP devices and equipment market. The urinary incontinence and pelvic organ prolapse devices and equipment industry is characterized by the increased use of several new technologies in recent years. There is a wide range of devices being developed to treat both POP and urinary incontinence. For instance, The Lyrette transurethral SUI system led by Verathon Medical UK Ltd is the only FDA-approved treatment used for the treatment of stress urinary incontinence (SUI) among women. Devices such as Lyrette transurethral SUI system are used for procedures for incontinence. The treatment through Lyretter does not require the use of anesthesia or surgery instead, it uses radiofrequency energy to tighten the tissue of the bladder. For the treatment of POP, companies are now focusing on using native tissue prolapse repair procedures instead of vaginal mesh after the adverse health issues from the usage of vaginal mesh were highlighted. Regulatory bodies, such as the FDA in the US, regulate the manufacturing and safety guidelines for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are required to obtain pre-market clearance (510(k)) of the tools specifically for implanting surgical mesh. FDA requires the manufacturers in urinary incontinence and pelvic organ prolapse devices and the equipment industry to conduct post-market studies to check the specific safety and effectiveness concerns related to surgical mesh used for the repair of POP. For example, FDA regulations resulted in many companies taking down their product completely from the market and made companies like Coloplast and Acell discontinue marketing of their products- Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix, respectively. Major players in the urinary incontinence & pelvic organ prolapse devices and equipment market are Boston Scientific Corporation, Coloplast Group, Ethicon US, C. R. Bard Inc., Johnson & Johnson, Teleflex Incorporated, Medtronic PLC., COVIDien, Cook Medical, and Neomedic. North America was the largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market in 2022. Western Europe was the second largest region in the urinary incontinence & pelvic organ prolapse devices and equipment market report. The regions covered in the urinary incontinence and pelvic organ prolapse devices and equipment analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the urinary incontinence & pelvic organ prolapse devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The urinary incontinence & pelvic organ prolapse devices and equipment market consist of sales of artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters that are used for the treatment of pelvic organ prolapse and urinary incontinence. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The urinary incontinence & pelvic organ prolapse devices and equipment market research report is one of a series of new reports from The Business Research Company that provides urinary incontinence & pelvic organ prolapse devices and equipment market statistics, including urinary incontinence and pelvic organ prolapse devices and equipment industry global market size, regional shares, competitors with urinary incontinence & pelvic organ prolapse devices and equipment market share, detailed urinary incontinence & pelvic organ prolapse devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary incontinence and pelvic organ prolapse devices and equipment industry. This urinary incontinence & pelvic organ prolapse devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary stone treatment devices and equipment are used in the treatment and management of stones formed in the kidneys and urinary tract. Kidney stones form when urine crystal-forming substances such as calcium, uric acid, and oxalate. The main products in the urinary stone treatment devices and equipment market are the extracorporeal shock wave lithotripsy devices, holmium laser devices, intracorporeal lithotripsy devices, stone retrieval devices, and ureteral stents. Holmium laser devices use pulsed laser and emit light at 2100 nm to break stones in the urinary tract. The stone types involved are calcium stones, struvite, uric acid, cystine, and drug-induced. The various end-users are hospitals, ambulatory surgery centres, and others. The global urinary stone treatment devices and equipment market is segmented - 1) By Product: Extracorporeal Shock Wave Lithotripsy Devices, Holmium Laser Devices, Intracorporeal Lithotripsy Devices, Stone Retrieval Devices, Ureteral Stents 2) By Stone Type: Calcium Stones, Struvite, Uric Acid, Cystine, Drug-Induced 3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users The global urinary stone treatment devices and equipment market size will grow from $2.84 billion in 2022 to $3.05 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global urinary stone treatment devices and equipment is expected to grow to $3.79 billion in 2027 at a CAGR of 5.6%. The increasing prevalence of Kidney Stones, especially in the geriatric population is driving the urinary stone treatment devices and equipment market growth. The incidence of urolithiasis is reported to be increasing across the globe. According to a study, about 30% of people around the world are obese and nearly 900 million people are geriatrics which is expected to increase to 1.4 billion by 2030. The incidence of kidney stones is globally increasing with an estimated prevalence ranging up to 15%. According to a Robotic Stone survey, the probability of stone formation in Saudi Arabia is 20.1% and 13% in the USA. Stone diseases or urolithiasis are frequent in the ageing population. The Asia-Pacific is presently home to more than half of the world’s ageing population above 60 years and the number is expected to rise to 2.45 billion by 2050. Major players in the urinary stone treatment devices and equipment market are Boston Scientific, Cook Medical, C.R. Bard, DirexGroup, Dornier MedTech, Bard Medical Division, Richard Wolf, Siemens Healthineers AG, Olympus Corporation, and Karl Storz. Lack of public awareness and proper knowledge about the problems associated with urinary stone diseases, particularly in under-developed countries acts as a major factor hindering the urinary stone treatment devices and equipment market growth. This lack of proper knowledge becomes a roadblock for the Urinary stone treatment device manufacturers because of many cases are unnoticed/unaddressed which amounts to a decrease in demand for these devices. For instance, according to a study conducted in Saudi Arabia, 44% of the participants had a family member suffering from urinary stone disease and 9.6% had urinary stones themselves, which suggests a high prevalence of the ailment in the country. But there was an incidence of lack of awareness and misconceptions among the people in most parts of that region. Companies in the industry are investing in advanced laser technology and robot-assisted surgeries to treat urolithiasis. Urolithiasis is a disease condition where calculi or stones are formed in the kidney, bladder, and urinary tract of the human body. Urolithiasis open surgeries are increasingly conducted with the help of minimally invasive procedures, advanced lasers, enhanced surgical tools, and robot-assisted devices to reduce hospitalization time, be less invasive and enable a shorter bladder catheterization time. For instance, Boston Scientific Co. is investing by way of an agreement with Lumenis, a company offering minimally-invasive clinical solutions, and holmium laser technology, to use and leverage the benefits of advanced laser technology. In May 2021, based on the guideline provided by the Food and Drug administration, a US-based regulator of medical devices and healthcare technology, Imperative Care Inc recalled Zoom 71 reperfusion Catheter due to the risk of breaking during use. If the device broke during use, it could leave fractured pieces inside the patient’s body resulting in serious injuries. North America was the largest region in the urinary stone treatment devices and equipment market in 2022. Western Europe was the second largest region in the urinary stone treatment devices and equipment market report. The regions covered in the urinary stone treatment devices and equipment analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the urinary stone treatment devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The urinary stone treatment devices and equipment market consist of sales devices such as extracorporeal shock wave lithotripsy devices, holmium laser devices, intracorporeal lithotripsy devices, stone retrieval devices, and ureteral stents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The urinary stone treatment devices and equipment market research report is one of a series of new reports from The Business Research Company that provides urinary stone treatment devices and equipment market statistics, including urinary stone treatment devices (or) equipment industry global market size, regional shares, competitors with a urinary stone treatment devices and equipment market share, detailed urinary stone treatment devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary stone treatment devices (or) equipment industry. This urinary stone treatment devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Laser technology refers to a device that will emit light through a method of optical amplification based on the stimulated emission of electromagnetic radiation. It is a narrow beam of concentrated light that has been produced by a special machine. It has been used for cutting very hard materials, and in many technical fields such as surgery and telecommunications. It is used to give high accuracy results in measuring small and large distances. The main types of laser technology are solid laser, liquid laser, and gas laser. Liquid lasers are optically pumped lasers in which the gain medium is a liquid at room temperature. The applications of laser technology include laser processing, optical communications, and other applications. The various end-users of laser technology include telecommunications, industrial, semiconductor and electronics, commercial, aerospace and defense, automotive, medical, research, and other end-users. The global laser technology market is segmented – 1) By Type: Solid Laser, Liquid Laser, Gas Laser 2) By Application: Laser Processing, Optical Communications, Other Applications 3) By End-User Industry: Telecommunications, Industrial, Semiconductor and Electronics, Commercial, Aerospace and Defense, Automotive, Medical, Research, Other End-Users The global laser technology market size grew from $12.52 billion in 2022 to $13.82 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of global laser technology is expected to grow to $20.11 billion in 2027 at a CAGR of 9.8%. Increased usage of consumer electronic gadgets is expected to propel the growth of the laser technology market going forward. Consumer electronics refer to electronic devices such as smartphones, television, and computers. Laser technology helps provide innovative solutions for the manufacturing of consumer electronics. For instance, in October 2021, according to The Economic Times, an Indian business newspaper, India has the highest mobile data consumption rate at 12 Gigabytes or GB per user a month in the world, and the country is adding 25 million new smartphone users every quarter. Therefore, increased usage of consumer electronic gadgets is expected to boost demand for laser technology market during the forecast period. Major players in the laser technology market are Trumpf lasers, Lumentum Operations LLC, Jenoptik AG, Novanta Photonics, Lumibird, Laser Star, Epilog Laser, Han’s Laser Technology Co., Ltd., MKS Instruments Inc., Gravotech Marking SAS, Lumenis Ltd., Toptica Photonics AG, Solaris Laser SA, Optotek and Medical, Alltec GmbH. Strategic collaborations are a key trend gaining popularity in the laser technology market. Companies operating in laser technology services are undergoing partnerships to enhance their new product development activities through mutual sharing of technologies and strengthen their market position. For instance, in February 2022, Trumpf, a German-based laser technology company, partnered with Marvel Fusion, a German-based startup developing a revolutionary fusion technique based on Chirped Pulse Amplification (CPA) lasers. This collaboration hopes to speed the development of their revolutionary fusion technology. Further, in March 2022, Tematys, a Scottish-based laser technology company collaborated with Chromacity, a UK-based manufacturer of compact femtosecond laser solutions and tunable optical parametric oscillators. This collaboration hopes to increase sales of its "ultrafast" technology to industrial companies in France. In January 2021, TRUMPF, a German based industrial machine manufacturing company has acquired an 80% stake in Active Fiber Systems GmbH (AFS), for an undisclosed amount. With this acquisition, TRUMPF plans to retain the AFS location in Jena and build on the research-driven company’s independent standing after finalizing the takeover as majority stakeholder. AFS is a Germany based company, develops, and manufactures ultrashort-pulse laser systems and fiber laser systems used primarily in science and research. Asia-Pacific was the largest region in the laser technology market in 2022. North America is expected to be the fastest-growing region in the laser technology market share during the forecast period. The regions covered in the laser technology market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the laser technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The laser technology market consists of sales of gas laser, solid-state laser, fiber lasers, dye lasers, and semiconductor laser. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The laser technology market research report is one of a series of new reports from The Business Research Company that provides laser technology market statistics, including laser technology industry global market size, regional shares, competitors with a laser technology market share, detailed laser technology market segments, market trends and opportunities, and any further data you may need to thrive in the laser technology industry. This laser technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nephrology and urology devices are used in the diagnosis and treatment of kidney and genitourinary diseases. The main types of nephrology and urology devices are dialysis devices and equipment, urinary stone treatment devices and equipment, urinary incontinence and pelvic organ prolapse devices and equipment, benign prostatic hyperplasia (BPH) treatment devices and equipment, and endoscopy devices and equipment. Dialysis devices and equipment is a machines used in dialysis that filter a patient's blood to remove excess water and waste products when the kidneys are damaged, dysfunctional, or missing. The dialysis machine itself is an artificial kidney. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global nephrology and urology devices market is segmented - 1) By Type: Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables The global nephrology and urology devices market size grew from $17.37 billion in 2022 to $18.63 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global nephrology and urology devices is expected to grow to $23.52 billion in 2027 at a CAGR of 6.0%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the nephrology and urology devices market during the historic period. According to the World Health Organization, the number of people aged 60 years and above was 1 billion in 2020 and the number will rise to 1.4 billion by 2030 and it will reach 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. These factors increased the demand for these products and drove the growth of the nephrology and urology devices market during the historic period. Major companies in the nephrology and urology devices market include Baxter International Inc., Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B. Braun Group, C. R. and Bard Inc. The nephrology and urology devices market was limited by the shortage of skilled workforce in most developed and developing countries, during the historic period. Equipment fabrication and integration require specialized skillsets relating to life sciences, pharmaceuticals, electronics, and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled labour was a significant deterrent to the growth of the market during the historic period. The nephrology and urology market is witnessing a rise in new product launches. Due to the high competition in the market, many companies are investing in advanced technologies to widen product portfolios and increase their share in the market. For instance, in March 2020, Medi-Tate an Israel-based medical device company received authorization for iTind system that is used to implant and remove nitinol devices during bladder neck remodelling. Researchers at Washington University in St. Louis, the University of Illinois at Urbana-Champaign, and Northwestern University together developed a wireless implant to control overactive bladder using LED lights. North America was the largest region in the global nephrology and urology devices market in 2022. Asia-Pacific was the second largest region in the global nephrology and urology devices market share. The regions covered in the nephrology and urology devices market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nephrology and urology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The nephrology and urology devices market consist of sales of instruments such as ureteral catheters, PCN catheters, urinary stents, stone baskets, urology guidewires, and renal dilators that are used to treat kidney and genitourinary diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The nephrology and urology devices market research report is one of a series of new reports from The Business Research Company that provides nephrology and urology devices market statistics, including nephrology and urology devices industry global market size, regional shares, competitors with a nephrology and urology devices market share, detailed nephrology and urology devices market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology and urology devices industry. This nephrology and urology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors, and they have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments for bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is a type of cancer that develops in the tissue that lines the inner surface of the bladder.There is no involvement of the bladder muscle. The different applications include low-grade tumors, and high-grade tumours and are distributed through various channels such as hospital pharmacies, retail pharmacies, and others. The global bladder cancer drugs market is segmented - 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels The global bladder cancer drugs market size will grow from $2.32 billion in 2022 to $2.66 billion in 2023 at a compound annual growth rate (CAGR) of 14.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global bladder cancer drugs is expected to grow to $4.31 billion in 2027 at a CAGR of 12.9%. The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, an increase in smoking habits, and consuming water that contains Arsenic increase the chances of blood cancer. According to the American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the bladder cancer drugs market. Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International, and Johnson & Johnson. The increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, the first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the bladder cancer drugs market. Major organizations are investing in the research to utilize nano-technology as a means to deliver drugs into the human body. Nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients because the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, the Center for Drug Research And Development in Canada pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology. The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there are subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments, a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for the time of tumor survival. Surrogate endpoints are used in clinical trials to save time and are especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration. The use of gene therapy is a key trend gaining popularity in the bladder cancer drug market. Gene therapy is a medical approach that treats or prevents disease by correcting the underlying genetic problem by altering a person's genetic makeup. For example, in December 2022, the US Food and Drug Administration (FDA), a federal agency of the Department of Health and Human Services in USA, approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. In August 2022, Merck & Co., a US-based pharmaceutical company, acquired Seagen for a deal amount of $40 billion. Through this acquisition, Merck & Co. expands its business in oncology. SeagenInc. is a US-based bio-technology company that develops various cancer drugs including bladder cancer drugs. North America was the largest region in the bladder cancer drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global bladder cancer drugs market during the forecast period. The regions covered in the global bladder cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bladder cancer drugs refer to drugs or medications that are used in the treatment of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors, and they have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments for bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. The bladder cancer drugs market consists of sales of Atezolizumab, Avelumab, Balversa, and Bavencio. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bladder cancer drugs market research report is one of a series of new reports from The Business Research Company that provides bladder cancer drugs market statistics, including bladder cancer drugs industry global market size, regional shares, competitors with a bladder cancer drugs market share, detailed bladder cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the bladder cancer drugs industry. This bladder cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global medical equipment is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the growth of the medical equipment market during the forecast period. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical equipment market data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market share. The regions covered in the medical equipment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the medical equipment market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified medical equipment market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the medical equipment market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global medical equipment market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, medical equipment market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs